RBC Capital maintains Nuvation Bio at Outperform, lowers price target to $17 from $20
Less than 1 min read
RBC Capital maintained Nuvation Bio at Outperform and lowered its price target to $17 from $20, a 15.0% decrease.
The price target implies an upside of 259.4% from the Nov 4 close of $4.73.
Explore more price target data and ratings for Nuvation Bio on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
Read the full article
Get unlimited access to analyst updates and every other article on TradingView.